Work

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Year: 2024

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2024.01.011

Authors: Paola Ghione, M. Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben

Institutions: Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Kite (United States), Vall d'Hebron Institute of Oncology, IPO Porto, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Hôpital Lyon Sud, Barts Cancer Institute

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391189122

FWCI: 0.697

Cites: 12

Cited by: 4

Related to: 10